Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed for KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.

被引：0

作者：

Kelly, Karen

Mazieres, Julien

Leighl, Natasha B.

Barlesi, Fabrice

Zalcman, Gerard

Gordon, Michael S.

Reckamp, Karen L.

Gandara, David R.

Gomez-Roca, Carlos Alberto

Bennouna, Jaafar

Cho, Byoung Chul

Park, Keunchil

Infante, Jeffrey R.

Richards, Donald A.

Wu, Yuehui

Schramek, Daniel J.

Cox, Donna S.

Gardner, Olivia S.

Peddareddigari, Vijay Gopal Reddy

Blumenschein, George R.

机构：

[1] UC Davis Comprehens Canc Ctr, Div Hematol & Oncol, Sacramento, CA USA

[2] Hop Larrey CHU Toulouse, Toulouse, France

[3] Princess Margaret Canc Ctr, Toronto, ON, Canada

[4] Aix Marseille Univ, Hop Nord, Assistance Publ Hop Marseille, Marseille, France

[5] Caen Univ Hosp, Caen, France

[6] Pinnacle Oncol Hematol, Scottsdale, AZ USA

[7] City Hope Comprehens Canc Ctr, Duarte, CA USA

[8] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA 95817 USA

[9] Inst Claudius Regaud, Toulouse, France

[10] Inst Cancerol Ouest, Nantes, France

[11] Yonsei Univ, Coll Med, Seoul, South Korea

[12] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[13] Sarah Cannon Res Inst, Nashville, TN USA

[14] Tennessee Oncol, Nashville, TN USA

[15] Texas Oncol, Houston, TX USA

[16] GlaxoSmithKline, Collegeville, PA USA

[17] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8027

引用

页数：1

共 50 条

[41] A phase 1/2 study of VS-6766 (RAF/MEK clamp) in combination with sotorasib (G12C inhibitor) in patients with KRAS G12C mutant non-small cell lung cancer (NSCLC) (RAMP 203).
Govindan, Ramaswamy
Awad, Mark M.
Gadgeel, Shirish M.
Pachter, Jonathan A.
Patrick, Gloria
Denis, Louis J.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[42] Binimetinib, pemetrexed (Pem) and cisplatin (Cis), followed by maintenance of Binimetinib and Pem in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations: The phase Ib SAKK 19/16 trial
Froesch, P. R.
Mark, M. T.
Rothschild, S. I.
Li, Q.
Godar, G.
Rusterholz, C.
Schmid, S.
Colombo, I.
Metaxas, Y.
Thut, H. E.
Sessa, C.
Gautschi, O.
Fruh, M.
ANNALS OF ONCOLOGY, 2020, 31 : S481 - S481
[43] The SHP2 Inhibitor RMC-4630 in Patients with KRAS-Mutant Non-Small Cell Lung Cancer: Preliminary Evaluation of a First-in-Man Phase 1 Clinical Trial
Ou, S. I.
Koczywas, M.
Ulahannan, S.
Janne, P.
Pacheco, J.
Burris, H.
McCoach, C.
Wang, J. S.
Gordon, M.
Haura, E.
Riess, J. W.
Zhu, V.
Ng, K.
Eckhardt, S. G.
Capasso, A.
Dua, R.
Chen, A.
Wang, Z.
Hayes, J.
Nichols, R.
Bivona, T.
JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (02) : S15 - S16
[44] Preliminary results from the phase 2 study of AFM24 in combination with atezolizumab in patients with EGFR wild-type (EGFR-WT) non-small cell lung cancer (NSCLC)
Kim, Hye Ryun
Saavedra, Omar
Cervantes, Andres
Lugowska, Iwona A.
Oberoi, Arjun
El-Khoueiry, Anthony B.
Thomas, Jacob Stephen
Rogowski, Wojciech
Lopez, Juanita Suzanne
Shim, Byoung Yong
Christenson, Eric
Boni, Valentina
Garassino, Marina Chiara
Yarza, Ramon
Gaertner, Ulrike
Lutkewitz, Sarah
Shuetz, Daniel
Pietzko, Kerstin
Emig, Michael
Espinosa, Daniela Morales
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[45] IMPACT OF KRAS CODON SUB-TYPES IN A PHASE II SECOND-LINE TRIAL IN KRAS-MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) OF SELUMETINIB PLUS DOCETAXEL VERSUS DOCETAXEL ALONE
Liptrot, Tom
Mann, Helen
Smith, Ian
Mcwalter, Gael
Dougherty, Brian
Walker, Jill
Orr, Maria C.
Hodgson, Darren
Shaw, Alice T.
Pereira, Jose Rodrigues
Jeannin, Gaelle
Vansteenkiste, Johan
Barrios, Carlos H. E.
Franke, Fabio A.
Crino, Lucio
Jaenne, Pasi A.
Smith, Paul
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S372 - S372
[46] Phase 1/2 Trial of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer (NSCLC)
Doebele, Robert
Horn, Leora
Spira, Alexander
Piotrowska, Zofia
Costa, Daniel
Neal, Joel
Reichmann, William
Kerstein, David
Li, Shuanglian
Janne, Pasi
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1072 - S1073
[47] Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial
Froesch, Patrizia
Mark, Michael
Rothschild, Sacha, I
Li, Qiyu
Godar, Gilles
Rusterholz, Corinne
Leibundgut, Elisabeth Oppliger
Schmid, Sabine
Colombo, Ilaria
Metaxas, Yannis
Koenig, David
Sessa, Cristiana
Gautschi, Oliver
Frueh, Martin
LUNG CANCER, 2021, 156 : 91 - 99
[48] An alternative schedule of oral vinorelbine tested as 2nd-line treatment on elderly patients with advanced non-small cell lung cancer (NSCLC):: A phase I feasibility trial.
de Petris, L
Migliorino, MR
de Santis, S
Saponiero, A
Condó, S
Di Salvia, R
de Marinis, F
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 702S - 702S
[49] Safety and efficacy of inetetamab in combination with pyrotinib in HER2 mutant patients with non-small cell lung cancer (NSCLC): An open-label, phase Ib trial
Fang, Wenfeng
Zhao, Yuanyuan
Huang, Yan
Zhang, Yaxiong
Hong, Shaodong
Huang, Yihua
Zhao, Hongyun
Yang, Yunpeng
Zhao, Shen
Chen, Gang
Zhou, Huaqiang
Ma, Yuxiang
Zhou, Ningning
Zhang, Li
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[50] A phase I dose escalation trial of BI 2536, a novel Plk1 inhibitor, with standard dose pemetrexed in previously treated advanced or metastatic non-small cell lung cancer (NSCLC)
Ellis, P. M.
Chu, Q. S.
Leighl, N. B.
Laurie, S. A.
Trommeshauser, D.
Hanft, G.
Munzert, G.
Gyorffy, S.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

← 1 2 3 4 5 →